| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | BUY | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 4.30▼ | 4.82▼ | 4.99▼ | 2.72▲ | 2.66▲ |
| MA10 | 4.56▼ | 4.73▼ | 3.70▲ | 2.51▲ | 2.50▲ |
| MA20 | 4.78▼ | 3.54▲ | 3.02▲ | 2.35▲ | 2.46▲ |
| MA50 | 4.95▼ | 2.81▲ | 2.60▲ | 2.34▲ | 2.46▲ |
| MA100 | 3.67▲ | 2.51▲ | 2.38▲ | 2.40▲ | 1.58▲ |
| MA200 | 2.96▲ | 2.38▲ | 2.37▲ | 2.75▲ | 2.46▲ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | -0.097▼ | 0.094▲ | 0.240▲ | 0.136▲ | 0.111▲ |
| RSI | 36.052▼ | 57.239▲ | 62.284▲ | 87.851▲ | 75.808▲ |
| STOCH | 10.734▼ | 50.379 | 62.791 | 71.937 | 38.507 |
| WILL %R | -94.118▼ | -58.635 | -58.635 | -58.857 | -58.712 |
| CCI | -111.752▼ | 19.797 | 61.224 | 466.667▲ | 456.728▲ |
| ▲ RSI&VOL | $VERU RSI Cross Up and Volume | Set Alert |
| ▲ RSI | $VERU RSI(14) Crossed Above 70 | Set Alert |
| RSI | $VERU RSI(14) Crossed Above 50 | Set Alert |
| ▲ MA | $VERU MA(20) Crossed Above MA(50) | Set Alert |
| MA | $VERU Price Crossed Above MA(200) | Set Alert |
| MA | $VERU Price Crossed Above MA(50) | Set Alert |
| MA | $VERU Price Crossed Above MA(13) | Set Alert |
| MA | $VERU Price Crossed Above MA(7) | Set Alert |
| ▼ GAP | $VERU Open Gap Down %3 | Set Alert |
| ▼ GAP | $VERU Open Gap Down %2 | Set Alert |
| ▲ BREAK | $VERU Price Breaks 60 Days High | Set Alert |
| ▲ BREAK | $VERU Price Breaks 30 Days High | Set Alert |
| ▲ BREAK | $VERU Price Breaks 20 Days High | Set Alert |
| ▲ BREAK | $VERU Price Breaks 10 Days High | Set Alert |
| CDL | $VERU Engulfing Candlestick Pattern Detected | Set Alert |
|
Thursday, June 04, 2026 07:22 AM
Veru Inc. (NASDAQ:VERU) has entered into a clinical supply agreement with Novo Nordisk A/S (NYSE:NVO) to support its upcoming Phase 2b PLATEAU study, which will investigate a combination treatment for ...
|
|
Thursday, June 04, 2026 07:22 AM
Veru Inc. (NASDAQ:VERU) has entered into a clinical supply agreement with Novo Nordisk A/S (NYSE:NVO) to support its upcoming Phase 2b PLATEAU study, which will investigate a combination treatment for ...
|
|
Wednesday, May 13, 2026 04:25 PM
Veru Inc (VERU) showcases positive Phase IIb trial outcomes and a strong cash position, but faces ongoing financial hurdles and competitive market pressures.
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 04/06/26 | 2.18 | 7.33 | 2.11 | 4.23 | 88,970,324 |
| 03/06/26 | 2.35 | 2.38 | 2.21 | 2.25 | 68,855 |
| 02/06/26 | 2.38 | 2.389 | 2.29 | 2.35 | 27,067 |
| 01/06/26 | 2.32 | 2.39 | 2.27 | 2.38 | 100,097 |
| 29/05/26 | 2.32 | 2.37 | 2.27 | 2.37 | 68,855 |
| 28/05/26 | 2.31 | 2.34 | 2.28 | 2.32 | 51,557 |
| 27/05/26 | 2.32 | 2.39 | 2.30 | 2.33 | 133,019 |
| 26/05/26 | 2.38 | 2.40 | 2.25 | 2.31 | 97,390 |
| 22/05/26 | 2.20 | 2.35 | 2.20 | 2.35 | 88,602 |
| 21/05/26 | 2.14 | 2.22 | 2.12 | 2.22 | 22,646 |
|
|
||||
|
|
||||
|
|